Previous 10 | Next 10 |
-- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24; Topline Phase 3 Data in Adults Expected in 2025 -- -- Received FDA Clearance of VAX-31 Adult IND Application; Phase 1/2 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024 -- ...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Vaxcyte Inc. (PCVX) is expected to report $-0.79 for Q3 2023
-- Company Expects to Initiate VAX-31 Phase 1/2 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 1/2 Study Expected in the Second Half of 2024 -- -- VAX-31 is a 31-Valent Pneumococcal Conjugate Vaccine De...
2023-10-16 18:25:10 ET Summary Vaxcyte, Inc. is making substantial progress with its vaccine candidate VAX-24 for the prevention of invasive pneumococcal disease as evidenced by trial data. Obtained positive immunogenicity data from its phase 2 study in adults for prevention of IP...
2023-10-16 10:34:11 ET More on Vaxcyte Strong Financials And Pipeline Position Vaxcyte For Success Seeking Alpha’s Quant Rating on Vaxcyte Historical earnings data for Vaxcyte Financial information for Vaxcyte For further details see: Vaxcy...
-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations -- -- Expanded Collaboration Builds on Vaxcyte’s Current Strategy to Conduct Initial Commercial Launch of VAX-24 in Adult...
2023-09-28 13:35:36 ET More on Vaxcyte Strong Financials And Pipeline Position Vaxcyte For Success Seeking Alpha’s Quant Rating on Vaxcyte Historical earnings data for Vaxcyte Financial information for Vaxcyte For further details see: Vaxcy...
SAN CARLOS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fires...
2023-09-14 13:21:48 ET Summary Sutro is developing mainly antibody-drug conjugates to address solid tumors. Their flagship molecule has shown both encouraging efficacy and concerning toxicity. The company has strengthened their balance sheet strategically, removing the short-t...
News, Short Squeeze, Breakout and More Instantly...
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Boa...
2024-06-23 20:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-23 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...